Study of a new drug for advanced non-squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called telisotuzumab adizutecan against the usual treatments for people with a type of lung cancer that has spread and has not responded to previous therapy. It may be an option if your cancer has a specific marker and you have not had certain other conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer that is advanced or has spread.
- Your cancer does not have a mutation in the EGFR gene.
- Your tumor shows a certain protein marker (c-Met) when tested in the lab.
- You are able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured and has not been treated with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
This trial tests two investigational drugs combined as a first treatment for people with a type of lung cancer called non-squamous non-small-cell lung cancer that has spread. The aim is to see if the combination is safe and effective.
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.